CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Genocea Biosciences Inc 's Long Term Debt to Equity

GNCA's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In Spite of the long-term debt repayement of -28.92%, in I Quarter 2022 ,Long Term Debt to Equity deteriorated to 0.24, below the Genocea Biosciences Inc 's average Long Term Debt to Equity.

Within Biotechnology & Pharmaceuticals industry in the first quarter 2022, 21 other companies have achieved lower Long Term Debt to Equity than Genocea Biosciences Inc in the I Quarter 2022. While Long Term Debt to Equity total ranking has deteriorated compared to the forth quarter 2021 from 842 to 1122 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt GNCA´s has?
What is the structure of GNCA´s Equity?


GNCA Long Term Debt to Equity (Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity Change 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Long Term Debt Change -61.47 % - - - 31.54 %
Long Term Debt to Equity MRQ 0.24 0.15 0.14 1.6 4.34
GNCA's Total Ranking # 1122 # 842 # 84 # 2471 # 2478
Seq. Equity Change -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Long Term Debt Change -28.92 % -22.17 % -17.97 % -15.1 % -



Long Term Debt to Equity first quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 22
Healthcare Sector # 183
Overall Market # 1122


Long Term Debt to Equity Statistics
High Average Low
4.34 0.71 0.11
(Mar 31 2021)   (Sep 30 2015)




Financial Statements
Genocea Biosciences Inc 's Equity $ 12 Millions Visit GNCA's Balance sheet
Genocea Biosciences Inc 's Long Term Debt $ 3 Millions Visit GNCA's Balance sheet
Source of GNCA's Sales Visit GNCA's Sales by Geography


Cumulative Genocea Biosciences Inc 's Long Term Debt to Equity

GNCA's Long Term Debt to Equity for the trailling 12 Months

GNCA Long Term Debt to Equity

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity TTM Growth 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Long Term Debt TTM Growth -61.47 % - - - 31.54 %
Long Term Debt to Equity TTM 0.23 0.33 0.37 0.4 0.2
Total Ranking TTM # 1291 # 95 # 0 # 117 # 91
Seq. Equity TTM Growth -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Long Term Debt TTM Growth -28.92 % -22.17 % -17.97 % -15.1 % -


On the trailing twelve months basis Due to long-term debt repayement of -28.92% Genocea Biosciences Inc decreased Long Term Debt to Equity in the 12 months ending in I Quarter 2022 to 0.23, below the company's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 35, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Genocea Biosciences Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the I Quarter 2022, compared to the prior period, from 95 to 1291.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt GNCA´s has?
What is the structure of GNCA´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 36
Healthcare Sector # 244
Within the Market # 1291


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
1.66 0.61 0.12
(Jun 30 2018)   (Dec 31 2020)




Companies with similar Long Term Debt to Equity in the quarter ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Long Term Debt to EquityMar 31 2022 MRQ Long Term DebtMar 31 2022 MRQ Equity
Pluri Inc   0.57 $ 22.924  Millions$ 40.143  Millions
Rubius Therapeutics Inc   0.57 $ 76.377  Millions$ 134.649  Millions
Biogen Inc   0.56 $ 6,275.700  Millions$ 11,220.700  Millions
Poseida Therapeutics Inc   0.56 $ 57.967  Millions$ 103.702  Millions
Codiak Biosciences Inc   0.53 $ 25.514  Millions$ 48.379  Millions
Greenlight Biosciences Holdings Pbc  0.53 $ 33.535  Millions$ 63.826  Millions
Sorrento Therapeutics Inc   0.42 $ 96.085  Millions$ 226.198  Millions
Qiagen N v   0.42 $ 1,471.898  Millions$ 3,466.611  Millions
Xtant Medical Holdings Inc   0.40 $ 11.844  Millions$ 29.283  Millions
Fennec Pharmaceuticals Inc   0.36 $ 4.489  Millions$ 12.524  Millions
Biomx Inc   0.35 $ 14.096  Millions$ 40.018  Millions
Candel Therapeutics Inc   0.32 $ 20.525  Millions$ 63.762  Millions
Neurocrine Biosciences Inc   0.27 $ 377.700  Millions$ 1,391.100  Millions
Humacyte Inc   0.27 $ 27.739  Millions$ 103.890  Millions
Scholar Rock Holding Corp  0.25 $ 43.620  Millions$ 171.316  Millions
Applied Genetic Technologies Corporation  0.24 $ 11.358  Millions$ 47.027  Millions
Genocea Biosciences Inc   0.24 $ 2.947  Millions$ 12.385  Millions
Eiger Biopharmaceuticals Inc   0.20 $ 19.446  Millions$ 97.267  Millions
Inmune Bio Inc   0.19 $ 14.514  Millions$ 75.642  Millions
Orchard Therapeutics Plc  0.17 $ 29.813  Millions$ 175.646  Millions
Logicbio Therapeutics Inc   0.17 $ 4.217  Millions$ 24.911  Millions
Surface Oncology Inc   0.17 $ 24.448  Millions$ 146.987  Millions
Bio techne Corp  0.14 $ 246.514  Millions$ 1,713.322  Millions
Tarsus Pharmaceuticals Inc   0.13 $ 19.180  Millions$ 149.197  Millions
Omega Therapeutics Inc   0.11 $ 19.880  Millions$ 181.354  Millions
Avrobio Inc   0.10 $ 15.020  Millions$ 143.163  Millions
Cannabis Global Inc.  0.09 $ 0.731  Millions$ 7.931  Millions
Sutro Biopharma Inc   0.06 $ 12.762  Millions$ 220.372  Millions
Zivo Bioscience Inc   0.05 $ 0.240  Millions$ 4.585  Millions

Date modified: 2023-03-25T04:00:08+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com